Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | ALPL | P05186 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | CBFB | Q13951 | 1/20 | 0.48 |
| ▸ | PLG | P00747 | 4/20 | 0.45 |
| ▸ | PLAU | P00749 | 4/20 | 0.45 |
| ▸ | F10 | P00742 | 3/20 | 0.45 |
| ▸ | F2 | P00734 | 2/20 | 0.45 |
| ▸ | PLAT | P00750 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6460680 | 0.88 | NPC1 (0.56) | SMN1; SMN2NPC1RAB9AL3MBTL1TDP1 | |
| SCHEMBL6452888 | 0.88 | PLG (0.48) | SMN1; SMN2NPC1RAB9APKMCBFB | |
| SCHEMBL6448821 | 0.86 | PLG (0.44) | SMN1; SMN2NPC1RAB9AL3MBTL1TDP1 | |
| SCHEMBL6451388 | 0.86 | PLG (0.45) | SMN1; SMN2NPC1RAB9AL3MBTL1TDP1 | |
| SCHEMBL6449844 | 0.82 | PLG (0.44) | L3MBTL1HSD17B10PLGPLAUF10 | |
| SCHEMBL6454710 | 0.81 | PLG (0.43) | CBFBPLGPLAUF10F2 | |
| SCHEMBL6448407 | 0.81 | HPGD (0.43) | SMN1; SMN2L3MBTL1HSD17B10PLGPLAU | |
| SCHEMBL6454173 | 0.80 | S1PR1 (0.47) | PLGPLAUF10F2PLAT | |
| SCHEMBL6460914 | 0.78 | PLG (0.41) | HSD17B10PLGPLAUF10F2 | |
| SCHEMBL16798918 | 0.77 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | SMN1; SMN2 4633/4885NPC1 59/4885RAB9A 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.